Related Experiment Video
Updated: Feb 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.3K
Could obesity be an infectious disease?
Summary
Obesity is complex, with gut microbiota influencing energy harvest and inflammation. Further research and clinical trials are needed to understand and combat this epidemic.
Area of Science:
- Microbiology
- Metabolic Health
- Obesity Research
Background:
- The global obesity epidemic remains a significant public health challenge, with current interventions proving insufficient.
- The underlying causes of obesity are more complex than commonly understood.
- Emerging scientific evidence implicates the gut microbiota in obesity development.
Purpose of the Study:
- To explore the role of gut microbiota in obesity.
- To investigate the mechanisms by which gut microbiota influences energy metabolism and inflammation.
- To identify potential therapeutic targets within the gut microbiota for obesity intervention.
Main Methods:
- Review of recent scientific data on gut microbiota and obesity.
- Analysis of the impact of gut microbiota on energy harvest and storage.
- Examination of the link between gut microbiota, inflammation, and gut barrier function.
Main Results:
- Gut microbiota influences obesity by affecting dietary energy harvest and storage, increasing energy efficiency.
- Gut microbiota contributes to obesity through low-grade inflammatory responses.
- Impairment of gut barrier function is associated with gut microbiota alterations in obesity.
Conclusions:
- The gut microbiota plays a critical role in the development of obesity.
- Characterizing and manipulating the gut microbiota offers a promising avenue for combating obesity and its comorbidities.
- Further clinical interventions and mechanistic studies are required to establish causality and develop effective strategies.
Related Concept Videos
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
301
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
301
Drug Dosing: Obese Patients
278
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
278
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
Infection
12.9K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
12.9K
Principles of Disease Surveillance
593
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
593

